In Reply We thank Fang et al for their interest in our study.1 Just eyeballing the progression-free and overall survival Kaplan-Meier curves, it is evident that survival experiences in both arms of the study are essentially similar without any meaningful difference. The restricted mean survival (event-free) time (RMST) up to a specific time point is an attractive new but seldom-used alternative approach to evaluate differences in the Kaplan-Meier curves, if the curves show apparent differences and the proportional hazards assumption is not plausible. When Kaplan-Meier curves overlap with no apparent differences, the proportional hazards assumption is redundant. Furthermore, the RMST approach needs a prespecification of time point because it varies with the time point at which we truncate our graphs for assessing clinically meaningful outcomes.
Pramanik R, Vishnubhatla S, Bakhshi S. Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors—Reply. JAMA Oncol. 2018;4(5):744. doi:10.1001/jamaoncol.2017.4891
Oncology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.